Medications and treatment plans are designed based on averages, but not everyone is average; a treatment that works for one might not work for another. In the new wave of personalized medicine, clinicians are tailoring treatment plans with the hope of helping those whose response is outside the average range.
An article on the BioTechniques website witten by Danielle Gerhard, PhD sheds quite a bit of light on the use of medicated microbiomes and area in which Optibiotix Health Plc (LON:OPTI) are quite at home. We caught up with Dr Stephen OHara for his thoughts on the article:
Stephen OHara, OptiBiotix Health Plc CEO said: ‘This article reflects the growing science on how the microbiome adversely effects a wide range of current therapies decreasing efficacy and causing a number of side effects. OptiBiotix has developed approaches which allow targeted modulation of the microbiome which can precision engineer the microbiome to enhance specific microbial groups and enzymes to optimise therapeutics responses and reduce side effects. As our understanding of the how specific microbial factors effect human health grows we can see precision engineering of the microbiome and the development of medicated microbiome therapies becoming the new frontier of modern medicine.’
